| Term | Description |
| Abbreviated New Drug Application (ANDA) |
A marketing approval application for a generic drug submitted to the US Food and Drug Administration.
|
| ACE (Inhibitor) |
Angiotensin-converting enzyme blocks the production of a hormone called angiotensin II. Angiotensin II narrows blood vessels and thereby raises blood pressure.
|
| ACS |
Acute Coronary Syndrome, an umbrella term used to cover any group of clinical symptoms compatible with acute myocardialischemia.
|
| Adjuvant |
Assisting in the prevention, improvement or cure of disease.
|
| ADP |
Adenosine diphosphate attaches to receptors on the surface of platelets to form blood clots.
|
| ADR |
American Depositary Receipt evidencing title to an ADS.
|
| ADS |
American Depositary Share representing one underlying Ordinary Share.
|
| Agonist |
A substance capable of binding to a molecular target to initiate or enhance a physiological reaction.
|
| Anaesthesia |
The total or partial loss of sensation, especially in relation to pain.
|
| Analgesia |
The inability to feel pain.
|
| Antagonist |
A substance capable of binding to a molecular target to neutralise or counteract a physiological reaction.
|
| Anti-androgen |
A drug that blocks the cellular uptake of testosterone by the prostate gland and used in the treatment of prostate cancer.
|
| Anti-psychotic drug |
For the treatment of the unrealistic ideas, delusions (false beliefs) and hallucinations (false perceptions) that can appear during depression or mania.
|
| Aromatase inhibitor |
A drug that inhibits the enzyme aromatase, which is involved in the production of the female sex hormone, oestrogen.
|
| AstraZeneca or AstraZeneca Group |
AstraZeneca PLC and its subsidiaries.
|
| Atherosclerosis |
Disease of the arteries linked to the build-up of lipids (fats) in the walls and the formation of atheromatous plaque, which contracts the lumen of these vessels.
|
| Atrial fibrillation (AF) |
Abnormal irregular heart rhythm with chaotic generation of electrical signals in the atria of the heart.
|
| Atypical anti-psychotic drugs |
Second generation drugs to treat psychosis with reduced likelihood to cause movement disorders.
|